Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | CD38 | P28907 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
| ▸ | FLT4 | P35916 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | MC5R | P33032 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3595867 | 0.79 | MAPT (0.51) | MAPTALDH1A1MAPK1MEN1KMT2A | |
| SCHEMBL12670825 | 0.74 | CA12 (0.56) | MAPTALDH1A1MAPK1MEN1KMT2A | |
| SCHEMBL5476110 | 0.74 | MEN1 (0.54) | MAPTMAPK1MEN1KMT2ACD38 | |
| SCHEMBL19664004 | 0.72 | ALDH1A1 (0.53) | MAPTALDH1A1MAPK1MEN1KMT2A | |
| SCHEMBL4342262 | 0.71 | HPGD (0.47) | MAPTALDH1A1MEN1KMT2ACD38 | |
| SCHEMBL4343469 | 0.71 | MEN1 (0.53) | MAPTALDH1A1MAPK1MEN1KMT2A | |
| SCHEMBL4342315 | 0.71 | HPGD (0.52) | MAPTALDH1A1MEN1KMT2ACD38 | |
| SCHEMBL26002147 | 0.70 | MEN1 (0.56) | MAPTALDH1A1MEN1KMT2ACD38 | |
| SCHEMBL6775761 | 0.70 | EGFR (0.44) | MAPTALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL15444359 | 0.70 | MEN1 (0.56) | MAPTMEN1KMT2ACD38SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048579-A1 | PYRIDAZINE-, PYRIDINE- AND PYRANE-DERIVATIVES AS GPBAR1 AGONISTS | ARISTA LUCA | 2010-02-25 | — | — | US | claimed |
| EP-2146970-A1 | PYRIDAZINE-, PYRIDINE- AND PYRANE-DERIVATIVES AS GPBAR1 AGONISIS | Novartis Ag (CH) | 2010-01-27 | — | — | EP | claimed |
| WO-2008125627-A1 | PYRIDAZINE-, PYRIDINE- AND PYRANE-DERIVATIVES AS GPBAR1 AGONISIS | NOVARTIS AG (CH) | 2008-10-23 | — | — | WO | claimed |
| US-20100048579-A1 | PYRIDAZINE-, PYRIDINE- AND PYRANE-DERIVATIVES AS GPBAR1 AGONISTS | ARISTA LUCA | 2010-02-25 | — | — | US | disclosed |
| EP-2146970-A1 | PYRIDAZINE-, PYRIDINE- AND PYRANE-DERIVATIVES AS GPBAR1 AGONISIS | Novartis Ag (CH) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008125627-A1 | PYRIDAZINE-, PYRIDINE- AND PYRANE-DERIVATIVES AS GPBAR1 AGONISIS | NOVARTIS AG (CH) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048579-A1 | PYRIDAZINE-, PYRIDINE- AND PYRANE-DERIVATIVES AS GPBAR1 AGONISTS | GPBAR1, GPER1, ADRB1 | MAPT 3054/4885ALDH1A1 558/4885MAPK1 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.